AG-270 MAT2A Inhibitor: Research Use Guidelines

AG-270 is a potent and selective small-molecule inhibitor of methionine adenosyltransferase 2A (MAT2A), designed to suppress S-adenosylmethionine (SAM) biosynthesis in MTAP-deleted tumor cells for mechanistic and translational oncology research.

Target

MAT2A (Methionine Adenosyltransferase 2A)

Mechanism

Inhibits SAM biosynthesis by binding MAT2A, reducing methyl-donor availability

Primary Research Application

MTAP-deleted cancer cell line studies; epigenetic and metabolic oncology assays

Recommended Storage

-20 °C, desiccated, protected from light; verify with SDS before use

Solubility (General Guidance)

Typically soluble in DMSO; aqueous solubility limited — confirm exact values with CoA

SKU

A655557 (Aladdin Scientific)

Overview and Mechanism of Action

AG-270 is a selective inhibitor of methionine adenosyltransferase 2A (MAT2A), the enzyme responsible for catalyzing the synthesis of S-adenosylmethionine (SAM) from methionine and ATP in most non-hepatic tissues. SAM is the principal biological methyl donor, supporting DNA, RNA, and histone methylation reactions critical to gene expression and cellular homeostasis.

Cancers harboring homozygous deletion of the MTAP gene (methylthioadenosine phosphorylase) exhibit a synthetic lethal dependency on MAT2A activity. Loss of MTAP leads to accumulation of its substrate methylthioadenosine (MTA), which allosterically modulates MAT2A. AG-270 exploits this vulnerability by potently suppressing MAT2A, selectively impairing SAM production and downstream methyltransferase activity in MTAP-null tumor cells relative to normal tissues.

Note: Specific IC₅₀ values and selectivity panel data for AG-270 should be verified against the current Certificate of Analysis (CoA) and peer-reviewed literature, as these parameters may vary by lot and assay format.

Handling, Storage, and Reconstitution

Storage: Store AG-270 at −20 °C in a tightly sealed vial under desiccating conditions and protected from light. Upon receipt, inspect the vial for integrity and record the lot number and expiry date. Avoid repeated freeze–thaw cycles, which can degrade compound potency.

Reconstitution: AG-270 is generally soluble in DMSO. As a standard starting point, prepare a 10–50 mM stock solution in anhydrous DMSO, aliquot into single-use volumes, and store at −20 °C. Always confirm solubility limits from the product CoA before preparation. When preparing aqueous working solutions, dilute DMSO stocks into the desired buffer or cell culture medium immediately before use, keeping the final DMSO concentration ≤0.1% (v/v) to minimize cytotoxic artifacts unless your assay has been validated at higher concentrations.

Safety: Handle in accordance with the Safety Data Sheet (SDS). Use appropriate PPE including gloves, lab coat, and eye protection. AG-270 is intended for research use only and must not be used in humans or animals.

Recommended Assay Protocols

Cell Line Selection: For maximum on-target effect, use isogenic cell line pairs differing only in MTAP status, or well-characterized MTAP-null cancer lines (e.g., certain glioblastoma, pancreatic, or lung cancer lines). Confirm MTAP deletion status by Western blot or genomic PCR prior to initiating studies.

Dose–Response Experiments: Prepare a minimum 8-point serial dilution series (e.g., 0.001–10 µM) in biological triplicate. Include a vehicle control (DMSO at matched concentration) and a positive control where available. Measure cell viability (e.g., CellTiter-Glo), SAM levels (LC-MS/MS metabolomics), or downstream histone methylation marks (e.g., H3K9me2 by ELISA or Western blot) as pharmacodynamic readouts.

Treatment Duration: MAT2A inhibition and consequent epigenetic effects typically require 48–96 hours of continuous compound exposure to manifest measurable changes in histone methylation. Shorter time points (4–24 h) are more appropriate for acute metabolite (SAM/MTA) quantification.

Controls: Always include a no-compound negative control, a vehicle control, and where possible a genetic control (e.g., MAT2A siRNA knockdown) to confirm on-target activity.

Data Interpretation and Troubleshooting

Expected Outcomes: In MTAP-null cells treated with AG-270, researchers should observe dose-dependent reductions in intracellular SAM, decreased global and locus-specific histone methylation, and (with prolonged treatment) anti-proliferative effects. MTAP-proficient control cells should show markedly attenuated responses, confirming selectivity.

Troubleshooting — Lack of Effect: Verify compound identity and concentration by LC-MS. Confirm MTAP status of the cell line. Ensure DMSO stock was not exposed to moisture (which can hydrolyze and inactivate the compound). Reassess treatment duration and serum concentration in media, as high serum can sequester small molecules.

Troubleshooting — Non-specific Toxicity: If toxicity is observed equally in MTAP-null and MTAP-proficient lines, reduce compound concentration or DMSO load. Prepare fresh dilutions from stock. Review off-target activity data in the literature and CoA.

Analytical Validation: Where possible, orthogonally validate MAT2A inhibition using a SAM quantification kit or targeted metabolomics in parallel with phenotypic readouts.

Regulatory and Compliance Notes

AG-270 (SKU: A655557) is supplied by Aladdin Scientific exclusively for in vitro research and preclinical laboratory use. It is not approved for therapeutic, diagnostic, veterinary, or any other clinical application. Users are responsible for ensuring that all experiments comply with applicable institutional biosafety, ethics, and chemical waste disposal regulations.

Dispose of AG-270 and all contaminated materials in accordance with local, national, and institutional hazardous chemical waste guidelines. Do not pour solutions containing AG-270 into the drain.

For lot-specific purity (HPLC), structural confirmation (NMR or HRMS), and exact physicochemical data, consult the Certificate of Analysis provided with each shipment or request it from Aladdin Scientific customer service.

Frequently asked questions

What is the primary research application of AG-270?

AG-270 is used primarily to study the synthetic lethal relationship between MTAP gene deletion and MAT2A activity in cancer cells. It enables researchers to investigate how suppression of SAM biosynthesis affects epigenetic regulation, methyltransferase activity, and tumor cell proliferation in MTAP-null models.

How should AG-270 stock solutions be prepared and stored?

Dissolve AG-270 in anhydrous DMSO to prepare a concentrated stock solution (typically 10–50 mM), aliquot to avoid freeze–thaw cycles, and store at −20 °C protected from light and moisture. Confirm exact solubility from the CoA supplied with your lot before preparation.

How can I confirm that the antiproliferative effect observed is due to MAT2A inhibition and not off-target toxicity?

Use isogenic MTAP-null and MTAP-proficient cell line pairs side by side. A selective MAT2A inhibitor should show significantly greater growth inhibition in MTAP-null cells. Complement phenotypic data with intracellular SAM quantification by LC-MS/MS, and include a MAT2A genetic knockdown (siRNA) as an orthogonal positive control to confirm on-target mechanism.

What downstream biomarkers are suitable for measuring MAT2A inhibition by AG-270?

Intracellular SAM levels (measured by LC-MS/MS) are the most direct pharmacodynamic biomarker. Downstream readouts include global histone methylation marks (e.g., H3K9me2, H4K20me2 by Western blot or ELISA), PRMT5 substrate symmetric dimethylarginine (SDMA) levels, and cell proliferation indices.

References

1. Mavrakis KJ, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351(6278):1208–1213. doi:10.1126/science.aad5944
2. Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214–1218. doi:10.1126/science.aad5214
3. Konteatis Z, et al. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021;64(8):4430–4449. doi:10.1021/acs.jmedchem.0c01895

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.